Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (71-80 of 150) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|October 1, 2010
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trialEvangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Magda Migkou, et al.
Scientific Reports|October 18, 2016
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate CancerSankar N Maity, Mark A Titus, Revekka Gyftaki, et al.
Cell|December 10, 2013
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockadeVivek K Arora, Emily Schenkein, Rajmohan Murali, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Future Oncology (London, England)|June 11, 2025
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: project RISEEamonn T Rogers, Thomas G Bognanno, Thomas Perkins, et al.
Urologic Oncology|May 19, 2024
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experienceSanjana Ranganathan, Carlos Riveros, Jiaqiong Xu, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Nature Reviews. Urology|January 14, 2026
A multi-modal approach for decision making in bladder cancerHasan Al-Sattar, Hao Ding, Oluchi Okoli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
Pageof 15

Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|October 1, 2010
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trialEvangelos Eleutherakis-Papaiakovou, Evangelos Kostis, Magda Migkou, et al.
Scientific Reports|October 18, 2016
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate CancerSankar N Maity, Mark A Titus, Revekka Gyftaki, et al.
Cell|December 10, 2013
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockadeVivek K Arora, Emily Schenkein, Rajmohan Murali, et al.
Clinical Genitourinary Cancer|August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus PrednisoneCharles J Ryan, Thian Kheoh, Jinhui Li, et al.
Future Oncology (London, England)|June 11, 2025
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: project RISEEamonn T Rogers, Thomas G Bognanno, Thomas Perkins, et al.
Urologic Oncology|May 19, 2024
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experienceSanjana Ranganathan, Carlos Riveros, Jiaqiong Xu, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Nature Reviews. Urology|January 14, 2026
A multi-modal approach for decision making in bladder cancerHasan Al-Sattar, Hao Ding, Oluchi Okoli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
Pageof 15